Cargando…

Risk for Clostridiodes difficile Infection among Older Adults with Cancer

Incidence was higher for patients with cancer, independent of prior healthcare-associated exposure.

Detalles Bibliográficos
Autores principales:	Kamboj, Mini, Gennarelli, Renee L., Brite, Jennifer, Sepkowitz, Kent, Lipitz-Snyderman, Allison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711221/ https://www.ncbi.nlm.nih.gov/pubmed/31442017 http://dx.doi.org/10.3201/eid2509.181142

Ejemplares similares

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

Estimating Risk of C. difficile Transmission from PCR Positive but Cytotoxin Negative Cases
por: Kamboj, Mini, et al.
Publicado: (2014)

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care
por: Klezovich-Bénard, Maria, et al.
Publicado: (2021)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

504. Change in Clostridium difficile Strain-Type Distribution After Implementation of Diagnostic Stewardship
por: McMillen, Tracy, et al.
Publicado: (2018)

The Association Between the Frequency of Interruptions in Antibiotic Exposure and the Risk of Health Care-Associated Clostridiodes difficile Infection
por: Song, Jiyoun, et al.
Publicado: (2020)

Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review
por: Gupta, Akshita, et al.
Publicado: (2021)

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
por: Kamboj, Mini, et al.
Publicado: (2008)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

Genotypic Correlation between Cases of Clostridium difficile (CDI) with Community-Onset Diagnosis after Recent Hospital Discharge and Their Prior Unit-Based Contacts
por: Aslam, Anoshé, et al.
Publicado: (2017)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

Two Groups of Cocirculating, Epidemic Clostridiodes difficile Strains Microdiversify through Different Mechanisms
por: Murillo, Tatiana, et al.
Publicado: (2018)

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

Rate and predictors of 30-day readmission for clostridiodes difficile: a United States analysis
por: Kichloo, Asim, et al.
Publicado: (2022)

747. Association of Clostridiodes difficile Infection Incidence With Renewed Vigor in Infection Prevention Practices With the Onset of the COVID-19 Pandemic
por: Khan, Ahmed A, et al.
Publicado: (2021)

Artificial Differences in Clostridium difficile Infection Rates Associated with Disparity in Testing
por: Kamboj, Mini, et al.
Publicado: (2018)

Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization
por: Pereira, Fátima C., et al.
Publicado: (2020)

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients
por: Morillas, Jose A, et al.
Publicado: (2019)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile
por: Sehgal, Kanika, et al.
Publicado: (2023)

Assessment of variation in 30‐day mortality following cancer surgeries among older adults across US hospitals
por: Lipitz‐Snyderman, Allison, et al.
Publicado: (2020)

Toxin Detection by Cell Culture Neutralization Assay [CYT] and Toxin based EIA [Tox EIA] among Recurrent Episodes of CDI Diagnosed by PCR
por: Kamboj, Mini, et al.
Publicado: (2017)

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B
por: Watson, Lauren, et al.
Publicado: (2019)

Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile
por: Bharathkar, Sonya Kumar, et al.
Publicado: (2023)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Electronic consent in clinical care: an international scoping review
por: Chimonas, Susan, et al.
Publicado: (2023)

2384. The Relationship Between Rifaxamin Use and the Prevalence of Clostridiodes difficile and Vancomycin-Resistant Enterococcus in Patients with Advanced Liver Disease
por: Alberto. De Jesus, Francisco, et al.
Publicado: (2019)

909 Comparison of three different data sources for Surgical Site Infection (SSI) Surveillance after Colon Surgery
por: Childers, Teresa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_klgbd0kkebrc96nv5fp2ca2128